Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other Routine +

Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

By The Northwire Desk — AI Analysis Apr 30, 2026 · 07:00 BLCO · 21.02 BAUSCH + LOMB CORPORATION
Executive Summary
  • Event: Bausch + Lomb will present over 40 scientific studies at the ARVO Annual Meeting in Denver (May 3-7, 2026).
  • Key Data Points: Presentations include Phase 2 trial results for BL1107 (glaucoma) and efficacy data for BL1312 (post-surgical pain).
  • Portfolio Updates: Clinical data provided for established products LUMIFY®, XIIDRA®, MIEBO® alongside pipeline assets like enVista Beyond™.
  • Context: This announcement follows the Q1 2026 Earnings Release on April 29, 2026, which raised full-year guidance and narrowed GAAP net losses significantly.
Material Impact
  • Primary Driver: The most recent news (ARVO presentation) is incremental validation of the pipeline but does not constitute a standalone material financial event compared to the Q1 earnings release issued one day prior.
  • Earnings Context: The April 29 earnings release was genuinely market-moving, raising FY26 revenue guidance to $5.42B-$5.52B (from $5.375B-$5.475B) and Adjusted EBITDA ex-IPR&D to $1.01B-$1.06B.
  • Profitability: GAAP net loss narrowed from $212M in Q1 2025 to $71M in Q1 2026, indicating operational improvement despite ongoing losses.
  • Pipeline Validation: The ARVO data supports the long-term growth narrative (Elios US launch, seeLYRA CE mark) but does not alter immediate financial projections.
  • Market Reaction: Stock price declined from $24.58 in late February to $21.02 by April 29, suggesting the market may have priced in the earnings or reacted to broader sector weakness despite the guidance raise.
BLCO · Price
Company Overview
  • Business Model: Diversified eye care company operating in Vision Care, Surgical, and Pharmaceuticals segments.
  • Flagship Products: MIEBO® (dry eye), XIIDRA® (dry eye), enVista® IOLs, LUMIFY® (redness relief).
  • Pipeline Focus: Glaucoma treatments (Elios™ laser, BL1107), AMD prevention (PreserVision AREDS3), and surgical lasers (seeLYRA™).
  • Strategic Shift: Transitioning from Bausch Health Companies Inc. to an independent entity with a focus on margin expansion and debt reduction.
Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 29, 2026 · 06:58

Bausch + Lomb Beats Q1 Estimates but Debt Overhang Persists Amid Turnaround Execution

Earnings